Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.
SinoMab BioScience Limited has announced the current composition of its board of directors, which includes a chairman and chief executive officer serving as executive director, two non-executive directors and five independent non-executive directors. The disclosure sets out the company’s latest governance structure for investors and regulators, clarifying the balance between executive oversight and independent supervision.
The company also detailed the membership and leadership of its three key board committees: audit, remuneration and nomination. By defining which directors chair and sit on these committees, SinoMab is signaling its focus on transparent corporate governance and regulatory compliance, providing stakeholders with clearer visibility into how oversight of financial reporting, pay and board appointments is organized.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 3681. The company operates in the life sciences and healthcare sector, focusing on the research, development and commercialization of innovative biologic therapies, primarily targeting immune-related and other serious diseases in global and regional markets.
Average Trading Volume: 5,103,077
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.37B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.